Will the Neuroimmunology Drug Development Summit (April 14, Boston) feature a publicly announced Phase 2 or Phase 3 clinical trial result for a multiple sclerosis drug, as confirmed by an official press release or published program summary?

A press release or official program summary published between April 14–16, 2026 on the summit organizer's website or a major newswire service announces Phase 2 or Phase 3 clinical trial results for a multiple sclerosis therapeutic presented at the April 14 Boston summit Source: Summit official program and press releases published at the organizing body's website or a newswire service such as PR Newswire (prnewswire.com) or BusinessWire (businesswire.com)